Wonbiogen Co., Ltd. (KOSDAQ:307280)
South Korea · Delayed Price · Currency is KRW 6,620.00
-340.00 (-4.89%)
At close: Apr 2, 2026
Wonbiogen Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 35,244 | 30,440 | 29,615 | 26,748 | 17,721 |
Other Revenue | -0 | -0 | -0 | -0 | -0 |
| 35,244 | 30,440 | 29,615 | 26,748 | 17,721 | |
Revenue Growth (YoY) | 15.78% | 2.79% | 10.72% | 50.94% | 47.46% |
Cost of Revenue | 17,476 | 16,202 | 15,469 | 14,325 | 10,173 |
Gross Profit | 17,769 | 14,238 | 14,146 | 12,423 | 7,548 |
Selling, General & Admin | 8,583 | 6,548 | 5,719 | 5,950 | 4,048 |
Research & Development | 723.49 | 838.47 | 504.15 | 492.1 | 584.71 |
Amortization of Goodwill & Intangibles | 57.79 | 55.76 | 68.82 | 67.66 | 63.19 |
Other Operating Expenses | 51.67 | 49.15 | 39.04 | 36.97 | 55.85 |
Operating Expenses | 9,577 | 8,022 | 7,108 | 7,372 | 5,508 |
Operating Income | 8,192 | 6,216 | 7,038 | 5,050 | 2,040 |
Interest Expense | -40.26 | -57.77 | -116.68 | -1,274 | -430.65 |
Interest & Investment Income | 269.44 | 304.07 | 279.71 | 128.25 | 47 |
Earnings From Equity Investments | -146.62 | 42.83 | -60.51 | - | - |
Currency Exchange Gain (Loss) | 46.4 | 150.8 | 49.99 | -44.9 | 42.36 |
Other Non Operating Income (Expenses) | -163.03 | -3.03 | -74.84 | -4.82 | -2,436 |
EBT Excluding Unusual Items | 8,158 | 6,653 | 7,115 | 3,855 | -737.83 |
Gain (Loss) on Sale of Investments | -90.5 | -32.64 | 48.67 | -200 | - |
Gain (Loss) on Sale of Assets | -124.47 | -1.38 | -7.13 | 11.69 | -57.7 |
Asset Writedown | -161.78 | -196.65 | - | - | - |
Pretax Income | 7,781 | 6,422 | 7,157 | 3,667 | -795.53 |
Income Tax Expense | 1,322 | 1,084 | 1,196 | 394.35 | -135.74 |
Earnings From Continuing Operations | 6,459 | 5,339 | 5,961 | 3,272 | -659.78 |
Minority Interest in Earnings | 156.15 | 350.98 | -463.77 | -66.38 | -56.42 |
Net Income | 6,615 | 5,690 | 5,497 | 3,206 | -716.2 |
Net Income to Common | 6,615 | 5,690 | 5,497 | 3,206 | -716.2 |
Net Income Growth | 16.27% | 3.50% | 71.46% | - | - |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 |
Shares Outstanding (Diluted) | 7 | 7 | 8 | 7 | 7 |
Shares Change (YoY) | -0.06% | -6.72% | 5.70% | 3.58% | 49.52% |
EPS (Basic) | 933.00 | 802.00 | 783.94 | 450.77 | -104.35 |
EPS (Diluted) | 933.00 | 802.00 | 725.00 | 445.00 | -105.00 |
EPS Growth | 16.33% | 10.62% | 62.92% | - | - |
Free Cash Flow | 6,512 | 8,201 | 3,189 | -711.95 | -1,254 |
Free Cash Flow Per Share | 918.37 | 1156.00 | 419.31 | -98.94 | -180.51 |
Dividend Per Share | - | - | 100.000 | 50.000 | - |
Dividend Growth | - | - | 100.00% | - | - |
Gross Margin | 50.42% | 46.77% | 47.77% | 46.44% | 42.59% |
Operating Margin | 23.24% | 20.42% | 23.76% | 18.88% | 11.51% |
Profit Margin | 18.77% | 18.69% | 18.56% | 11.99% | -4.04% |
Free Cash Flow Margin | 18.48% | 26.94% | 10.77% | -2.66% | -7.08% |
EBITDA | 9,699 | 7,863 | 8,607 | 6,249 | 2,921 |
EBITDA Margin | 27.52% | 25.83% | 29.06% | 23.36% | 16.48% |
D&A For EBITDA | 1,507 | 1,647 | 1,569 | 1,199 | 881.58 |
EBIT | 8,192 | 6,216 | 7,038 | 5,050 | 2,040 |
EBIT Margin | 23.24% | 20.42% | 23.76% | 18.88% | 11.51% |
Effective Tax Rate | 16.99% | 16.87% | 16.71% | 10.75% | - |
Advertising Expenses | 1,939 | 1,113 | 881.91 | 1,184 | 700.07 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.